Worth Watching: Will Vertex Pharmaceuticals Incorporated Go Down Anytime Soon?

Worth Watching: Will Vertex Pharmaceuticals Incorporated Go Down Anytime Soon?

The stock of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is a huge mover today! About 2.62M shares traded hands or 26.57% up from the average. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) has risen 8.95% since April 8, 2016 and is uptrending. It has outperformed by 3.30% the S&P500.
The move comes after 9 months positive chart setup for the $26.79 billion company. It was reported on Nov, 10 by Barchart.com. We have $120.63 PT which if reached, will make NASDAQ:VRTX worth $6.70 billion more.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Ratings Coverage

Out of 15 analysts covering Vertex Pharmaceuticals (NASDAQ:VRTX), 9 rate it a “Buy”, 0 “Sell”, while 6 “Hold”. This means 60% are positive. Vertex Pharmaceuticals has been the topic of 29 analyst reports since July 31, 2015 according to StockzIntelligence Inc. The firm has “Hold” rating by Jefferies given on Wednesday, September 9. Morgan Stanley upgraded the stock to “Overweight” rating in Friday, October 2 report. The firm earned “Perform” rating on Thursday, February 11 by Oppenheimer. On Friday, October 30 the stock rating was upgraded by H.C. Wainwright to “Buy”. The firm earned “Overweight” rating on Monday, September 14 by Barclays Capital. The stock of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) earned “Neutral” rating by Goldman Sachs on Thursday, April 28. The firm earned “Buy” rating on Thursday, February 4 by Argus Research. Vetr upgraded Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) rating on Tuesday, September 1. Vetr has “Buy” rating and $143.70 price target. The firm has “Buy” rating given on Tuesday, December 1 by Stifel Nicolaus. Jefferies maintained it with “Buy” rating and $105 target price in Wednesday, October 5 report.

According to Zacks Investment Research, “Vertex Pharmaceuticals Inc. discovers, develops and markets small molecule drugs that address major unmet medical needs. The company has eight drug candidates in clinical development to treat viral diseases, inflammation, cancer, autoimmune diseases and neurological disorders. Vertex has created its pipeline using a proprietary information-based approach to drug design that integrates multiple technologies in biology, chemistry and biophysics aimed at increasing the speed and success rate of drug discovery. (PRESS RELEASE)”

Insitutional Activity: The institutional sentiment increased to 1.14 in 2016 Q2. Its up 0.18, from 0.96 in 2016Q1. The ratio is positive, as 53 funds sold all Vertex Pharmaceuticals Incorporated shares owned while 139 reduced positions. 43 funds bought stakes while 176 increased positions. They now own 236.53 million shares or 0.67% less from 238.13 million shares in 2016Q1.
First Allied Advisory Svcs has 8,940 shares for 0.04% of their US portfolio. Lazard Asset Mngmt Ltd Company has 0.25% invested in the company for 1.25 million shares. Timessquare Capital Mgmt Ltd Com owns 709,910 shares or 0.4% of their US portfolio. Endurant Capital Mgmt Lp, a California-based fund reported 6,250 shares. First Interstate State Bank accumulated 50 shares or 0% of the stock. Moreover, Intact Investment Management has 0.02% invested in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) for 6,600 shares. Blackrock Advsrs Lc has 0.13% invested in the company for 1.51M shares. Hirtle Callaghan & Co Limited Liability Com has 0% invested in the company for 218 shares. Ig Invest Mngmt Limited accumulated 0.03% or 91,408 shares. Natl Planning holds 0.03% of its portfolio in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) for 4,487 shares. Etrade Cap Limited Liability Corporation, a New York-based fund reported 2,937 shares. Raymond James Na has invested 0.03% of its portfolio in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). The California-based Symphony Asset Limited Com has invested 0.12% in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Seven Eight Ltd has 0.1% invested in the company for 3,500 shares. Capstone Asset Co holds 0.06% of its portfolio in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) for 23,831 shares.

Insider Transactions: Since May 11, 2016, the stock had 0 buys, and 28 selling transactions for $16.81 million net activity. $505,400 worth of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) was sold by BOGER JOSHUA S. $104,444 worth of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) was sold by Arbuckle Stuart A. Shares for $16,576 were sold by SMITH IAN F. Silva Paul M sold 202 shares worth $16,576. 117 shares were sold by Sachdev Amit, worth $9,555.

More news for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) were recently published by: Fool.com, which released: “Vertex Pharmaceuticals Incorporated Pushes Forward With Drug Combinations (and …” on October 27, 2016. Nasdaq.com‘s article titled: “Earnings Reaction History: Vertex Pharmaceuticals Incorporated, 55.6% Follow …” and published on October 25, 2016 is yet another important article.

VRTX Company Profile

Vertex Pharmaceuticals Incorporated (Vertex), incorporated on January 4, 1989, is engaged in the business of discovering, developing, manufacturing and commercializing medicines for serious diseases. The Firm operates in pharmaceuticals segment. The Company’s business is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications. Vertex’s two marketed medicines are ORKAMBI and KALYDECO, which are approved to treat patients with CF having specific mutations in their CF transmembrane conductance regulator (CFTR) gene. It has multiple development programs in the field of CF, including VX-661, VX-371, and VX-152 and VX-440. The Company’s VX-661 is a corrector compound that the Company is evaluating a Phase III development program in combination with ivacaftor in multiple CF patient populations having approximately one copy of the F508del mutation in their CFTR gene. The Company’s VX-371 is an investigational epithelial sodium channel (ENaC) inhibitor that is being evaluated in a Phase II development program. The Company’s VX-152 and VX-440 are two next-generation CFTR corrector compounds that entered Phase I clinical trials.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Tags: , ,

Leave a Comment